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JSPH Fellows Reflect
The U.S. healthcare landscape is undergoing
considerable change, driven in large part
by the provisions of the Patient Protection
and Affordable Care Act (ACA). The
regulations codified in the ACA have
deliberately realigned incentives for
stakeholders to improve the value of health
care. This focus on value is driven by the
shortcomings of traditional reimbursement
models such as fee-for-service (paying
for procedures and tests without regard
to evidence as to their appropriateness or
utility), which has resulted in substandard
quality and efficiency. Moreover, the
consequence of these perverse financial
incentives is poor health outcomes and
exorbitant costs. As a result, the dual issues
of improving health outcomes and reducing
overall costs have been the subject of
countless health policy debates and thus the
emphasis of our fellowship at the Jefferson
School of Population Health (JSPH).
For 20 years, the objective of the JSPH
post-doctoral fellowship program has
been to foster the development of health
professionals with an interest in outcomes
research to examine the cost, quality, and
policies applied within the healthcare
system. These primary objectives are
met through linking health economic
constructs in our didactic coursework with
research projects that span health services
research, outcomes research, and health
economic analysis. Our research projects
during the first year of the fellowship
have ranged from developing innovative
tools for communicating health economics
and outcomes research (HEOR) evidence
to financial stakeholders, to working on
deliverables related to the clinical and
financial underpinnings of new models

of primary care. As newly minted
pharmacists, this bolus dose of exposure
through our research projects has afforded
us the opportunity to witness firsthand the
paradigm shift in health care from volume
to value-based care.
While some parts of the ACA took effect
before our time at JSPH, the beginning
of our fellowship was marked by highly
debated issues, such as the individual
mandate and Medicaid expansion. At the
time, the implications of these policies
and their relationship to the scope of our
fellowships were uncertain. However, over
the course of the year we were able to
draw on our formal training, experiences
at national conferences, and dedicated
discussions with experts in the field to
better understand their implementation.
Reflecting on these last 9 months, we
witnessed several responses to these
policies including the government
shutdown, changes in employer coverage,
and the ultimate March 31st enrollment
numbers through the shrewd lens of
apprentices in outcomes research. As we
complete the final stretch of our first year,
we have witnessed the beginning of a
revolution grounded in value-based care.
The collaborative approach to our training
at JSPH has given us a clear understanding
of how patients, providers, payers, and
other stakeholders are beginning to
piece together their roles in this evolving
landscape focused on value. This rich
insight will serve us well as we move to
the next phase of our fellowship in the
pharmaceutical industry. Our contribution
in this setting is correspondingly aligned
with the pharmaceutical industry’s
mission to deliver transformational
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evidence to a variety of stakeholders that
support decision-making on the value of
pharmaceutical agents.
In the 20 years that JSPH has offered
this fellowship, no two experiences have
been exactly alike, and we believe this is
certainly the case regarding our opportune
time to be a part of the legacy of this
program. Our experience at JSPH has
given us a glimpse of how research can
help generate transformational evidence
that will contribute to the nation’s goal of
providing valuable care through containing
cost and improving health outcomes. 
Click here for more information about
the HEOR fellowship program.
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